VANCOUVER, BC / ACCESSWIRE /April 9, 2024 / Gemina Laboratories Ltd . (CSE:GLAB)(FRA:8I7) (the " Company " or " Gemina ") today announces that it has licensed a novel biosensing architecture from the University of British Columbia. This licence is the culmination of a programme of research commenced between Gemina and the University of British Columbia in 2021. It lays the foundation for expanding Gemina's technology... Read More

VANCOUVER, BC / ACCESSWIRE / April 2, 2024 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the " Company " or " Gemina ") is pleased to announce the signing of a license agreement with a significant global diagnostics company. The license agreement is the culmination of Gemina's commercialization program to date and will enable our new licensing partner to develop, manufacture and sell new products using Gemina's IP... Read More

VANCOUVER, BC / ACCESSWIRE / March 21, 2024 / Gemina Laboratories Ltd. (CSE:GLAB) (FRA:8I7) (the " Company " or " Gemina ") is pleased to provide a strategic update and outlook for 2024 and beyond. The Company is beginning to see results from its 2023 focus on developing large scale commercial partnerships. Our emphasis on developing multiple revenue streams, including product development, licenses, and services, will... Read More

VANCOUVER, BC / ACCESSWIRE / March 19, 2024 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the " Company " or " Gemina ") is pleased to announce that further to its news release dated February 22, 2024, it has raised gross proceeds of $910,000 under its non-brokered private placement (the " Private Placement ") of unsecured convertible notes of the Company (the " Notes "). Please see the Company's news release dated... Read More

VANCOUVER, BC / ACCESSWIRE / November 6, 2023 / Gemina Laboratories Ltd. (CSE:GLAB) (FRA:8I7), a diagnostics technology company, is pleased to announce that it has appointed the global investment bank Stifel as its sole and exclusive financial advisor to the Company, as it considers strategic licensing and partnership opportunities for its breakthrough diagnostics technology. Gemina is targeting a series of significant... Read More

VANCOUVER, BC / ACCESSWIRE / July 25, 2023 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the " Company " or " Gemina ") is excited to announce another major innovation in lateral flow assay ("LFA") test design resulting from its innovative, patented Gemina Bridge chemistry platform. Gemina Labs has deployed cellulose (paper) test strips in the lateral flow assay format, a fully biodegradable, environmentally friendly... Read More

Gemina to present achievement of another significant technical milestone. VANCOUVER, BC / ACCESSWIRE / June 15, 2023 / Gemina Laboratories Ltd. (CSE:GLAB) (FRA:8I7), a specialist in fast, affordable, and accurate diagnostic tests, is pleased to announce the company's attendance at the American Association of Clinical Chemistry ("AACC") Annual Scientific Meeting & Clinical Lab Expo running from Sunday, July 23rd, 2023 to... Read More

VANCOUVER, BC / ACCESSWIRE / June 5, 2023 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7), a specialist in fast, affordable, and accurate diagnostic tests, is delighted to announce significant technical results from its collaboration with ReadyGo Diagnostics Ltd. ("ReadyGo"), an isothermal molecular diagnostics developer based in Bath, UK. This represents the first step of Gemina's move into molecular diagnostics adding... Read More

VANCOUVER, BC / ACCESSWIRE / May 17, 2023 / Gemina Laboratories Ltd. (CSE:GLAB) (FRA:8I7) (the " Company " or " Gemina ") is delighted to announce that its patented chemistry for Antibody Immobilization allows for a massive reduction in antibody usage when used in lateral flow assay ("LFA") diagnostic tests. This represents the confirmation of a major technical milestone on the LFA format for Gemina. The Antibody... Read More

VANCOUVER, BC / ACCESSWIRE / March 27, 2023 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the " Company " or " Gemina ") is pleased to announce that it will host a live investor webinar presentation on Thursday, March 30, 2023 at 2:00 PM ET. During the webcast, Brian Firth, CEO, will conduct a presentation that will cover key areas of Gemina's business. After the formal presentation, participants will have the opportunity... Read More

VANCOUVER, BC / ACCESSWIRE / March 7, 2023 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the " Company " or " Gemina ") is delighted to announce that it has appointed Martha Najib as an independent director of the Company. Ms. Najib brings an exceptionally strong and accomplished record in the diagnostics industry to Gemina. With more than 20 years of award-winning US and global healthcare experience, she is highly... Read More

VANCOUVER, BC / ACCESSWIRE / January 25, 2023 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the " Company " or " Gemina ") is delighted to announce the appointment of Dr. Bola Grace to the Board of Directors. Dr. Grace brings extensive leadership experience in the biotech/healthcare industry to the Board, having provided strategic, commercial and technical direction on many complex programmes, delivering numerous... Read More

VANCOUVER, BC / ACCESSWIRE / January 23, 2023 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the " Company " or " Gemina ") is delighted to announce that it has appointed Dr. Stefan Hamill as Vice President, Strategy of the Company. Dr. Hamill, based in London, was most recently with the UK-based mid and small-cap investment bank Numis, which he helped transform into the #1 corporate franchise in UK Life Sciences. During... Read More

VANCOUVER, BC / ACCESSWIRE / January 10, 2023 / Gemina Laboratories Ltd. (CSE:GLAB) (FRA:8I7) (the " Company " or " Gemina ") is pleased to provide the following strategic overview and share an outlook for 2023 and beyond. The Company enters 2023 at a significant inflection point in its growth, maturing from its primary focus on R&D and proof of concept work, to the development of large-scale commercial partnerships and... Read More

VANCOUVER, BC / ACCESSWIRE / January 6, 2023 / Gemina Laboratories Ltd. (CSE:GLAB) (FRA:8I7) (the " Company " or " Gemina ") is pleased to announce the completion of its influenza A/B rapid test prototype. The Company announced its intention to develop an influenza diagnostic in Q2 of 2022, using Gemina's unique chemistry platform. Influenza A/B Demand for tests for influenza and other common illnesses has been growing... Read More

VANCOUVER, BC / ACCESSWIRE / December 20, 2022 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the " Company " or " Gemina ") is delighted to announce Dr. Michael Shannon has been appointed to constitute and Chair the Company's Clinical Advisory Board. Dr. Shannon is one of Canada's pre-eminent public health leaders. He spent 31 years in the Canadian Forces, retiring at the rank of Commodore (Brigadier General equivalent) as... Read More

VANCOUVER, BC / ACCESSWIRE / December 19, 2022 / Gemina Laboratories Ltd. (CSE:GLAB) (FRA:8I7) (the " Company " or " Gemina ") is pleased to announce that it has entered into a collaborative research partnership focused on the development of wearable biosensors with Dr. Amanda Clifford at the University of British Columbia. Dr. Clifford is a researcher and Assistant Professor at the UBC Department of Materials Engineering.... Read More

VANCOUVER, BC / ACCESSWIRE / December 13, 2022 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the " Company " or " Gemina ") is pleased to announce that RAPIvD Limited (" RAPIvD ") has met an important regulatory milestone. On December 7, 2022, Gemina announced that it had entered into a definitive share exchange agreement to acquire 19% of the issued and outstanding shares of RAPIvD with the option, subject to certain... Read More

VANCOUVER, BC / ACCESSWIRE / December 7, 2022 / Gemina Laboratories Ltd. (CSE:GLAB) (FRA:8I7) (the " Company " or " Gemina ") is pleased to announce that the Company has entered into a definitive share exchange agreement (the " Definitive Agreement ") with RAPIvD Limited (" RAPIvD ") and the holders (the " RAPIvD Shareholders ") of the ordinary shares of RAPIvD (the " RAPIvD Shares "). Pursuant to the Definitive Agreement,... Read More